Skip to main content

Table 2 Primary and secondary outcomes

From: Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib

Outcomes

Without CVD

CVD

Total

p-value

Odds ratio (95% Confidence interval)

Afiba

7

17

10

0.02

Adjusted: 2.91 (1.19-7.25)

Discontinuation

31

44

35

0.08

Unadjusted: 1.71 (0.95-3.08)

Bleeding

16

19

17

0.65

Unadjusted: 1.20 (0.55-2.61)

     

Hazards ratio (95% Confidence interval)

Mortalityb

23

39

28

0.01

Adjusted: 1.90 (1.06-3.41)

  1. aAdjusted for age, hypertension, chronic kidney disease, and ibrutinib initiation dose
  2. bAdjusted for age, new-onset atrial fibrillation, and cancer diagnoses